These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
1541 related items for PubMed ID: 18187944
1. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944 [Abstract] [Full Text] [Related]
2. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB. J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160 [Abstract] [Full Text] [Related]
3. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Lebwohl M, Papp K, Han C, Schenkel B, Yeilding N, Wang Y, Krueger GG. Br J Dermatol; 2010 Jan; 162(1):137-46. PubMed ID: 19903183 [Abstract] [Full Text] [Related]
4. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. Health Qual Life Outcomes; 2006 Sep 27; 4():71. PubMed ID: 17005043 [Abstract] [Full Text] [Related]
5. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA. J Dermatolog Treat; 2007 Sep 27; 18(1):25-31. PubMed ID: 17365264 [Abstract] [Full Text] [Related]
6. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. Revicki DA, Willian MK, Menter A, Gordon KB, Kimball AB, Leonardi CL, Langley RG, Kimel M, Okun M. J Dermatolog Treat; 2007 Sep 27; 18(6):341-50. PubMed ID: 18058494 [Abstract] [Full Text] [Related]
7. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB. Br J Dermatol; 2005 May 27; 152(5):954-60. PubMed ID: 15888152 [Abstract] [Full Text] [Related]
8. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Spuls PI, Hooft L. Br J Dermatol; 2012 Oct 27; 167(4):710-3; discussion 714-5. PubMed ID: 23013312 [Abstract] [Full Text] [Related]
9. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, Camez A. Br J Dermatol; 2008 Mar 27; 158(3):549-57. PubMed ID: 18047521 [Abstract] [Full Text] [Related]
10. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A. Br J Dermatol; 2008 Sep 27; 159(3):704-10. PubMed ID: 18627375 [Abstract] [Full Text] [Related]
11. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Reich K, Nestle FO, Papp K, Ortonne JP, Wu Y, Bala M, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE. Br J Dermatol; 2006 Jun 27; 154(6):1161-8. PubMed ID: 16704649 [Abstract] [Full Text] [Related]
12. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Health Qual Life Outcomes; 2008 Oct 02; 6():75. PubMed ID: 18831744 [Abstract] [Full Text] [Related]
13. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM. Am J Clin Dermatol; 2011 Feb 01; 12(1):51-62. PubMed ID: 21110526 [Abstract] [Full Text] [Related]
14. Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial. Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani PM. Br J Dermatol; 2012 Dec 01; 167(6):1374-81. PubMed ID: 22897348 [Abstract] [Full Text] [Related]
15. The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Reich K, Griffiths CE. Arch Dermatol Res; 2008 Nov 01; 300(10):537-44. PubMed ID: 18784934 [Abstract] [Full Text] [Related]
16. Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial. Tsai TF, Song M, Shen YK, Schenkel B, Choe YB, Kim NI, Lee JH, Lee JH, Song HJ, Youn JI, PEARL investigators. J Drugs Dermatol; 2012 Aug 01; 11(8):943-9. PubMed ID: 22859239 [Abstract] [Full Text] [Related]
17. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P. J Am Acad Dermatol; 2010 May 01; 62(5):812-8. PubMed ID: 20219265 [Abstract] [Full Text] [Related]
18. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Krueger GG, Langley RG, Finlay AY, Griffiths CE, Woolley JM, Lalla D, Jahreis A. Br J Dermatol; 2005 Dec 01; 153(6):1192-9. PubMed ID: 16307657 [Abstract] [Full Text] [Related]
19. An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab. Vender R. J Drugs Dermatol; 2011 Apr 01; 10(4):396-402. PubMed ID: 21455550 [Abstract] [Full Text] [Related]
20. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. Torii H, Sato N, Yoshinari T, Nakagawa H, Japanese Infliximab Study Investigators. J Dermatol; 2012 Mar 01; 39(3):253-9. PubMed ID: 22211581 [Abstract] [Full Text] [Related] Page: [Next] [New Search]